ISSN (Online) 2394-2320

International Journal of Engineering Research in Computer Science and Engineering (IJERCSE)

Volume 13, Issue 9, September 2026

Schizophrenia in the Era of Neuroimaging and Artificial Intelligence

[1] M.R. Meshram, [2] Dr. A.D. Sakhare

[1] Research Scholar, R. T. M. Nagpur University, Nagpur, Maharashtra, India
[2] Department of Electronics and Computer Science, R. T. M. Nagpur University, Nagpur, Maharashtra, India
*Corresponding Author Email: [1] mihir25_2010@rediffmail.com, [2] ezeokechukwu0273@pg.babcock.edu.ng

Abstract*— *Schizophrenia is a serious neuropsychiatric disorder characterized by a prevalence rate of 0.5%-1% across the world that is one of the main causes of disability around the world. Schizophrenia is a heterogeneous disorder consisting of positive symptoms like hallucinations and delusions, negative symptoms like flat affect and social isolation, and cognitive dysfunction related to attention, memory, and executive functions. All of these result in poor functioning, low quality of life, and increased mortality among others. Although many studies have been performed over the years to understand schizophrenia better, the mechanism of the illness has still not been discovered, resulting in a lack of proper diagnosis and treatment methods for the illness. However, recent advancements in neuroimaging, genomics, and artificial intelligence have made the study of schizophrenia possible through improved ability to characterize abnormalities in the brain and biomarker identification for the illness. This paper provides a comprehensive analysis of the causality, neurobiology, symptoms, and treatment methods of schizophrenia, with a focus on neuroimaging and artificial intelligence.

Keywords: Schizophrenia, Neuroimaging, Artificial Intelligence, Machine Learning, MRI, Cognitive Dysfunction.

I. INTRODUCTION

Schizophrenia is a complex mental illness that impacts awareness, perception, emotional responses, and behavior. People suffering from Schizophrenia usually have abnormalities in their perception of reality, such as hallucinations, delusions, disorganized speech, and unusual behavior. Such symptoms affect people's social functioning, work efficiency, and daily activities significantly (Raju, 2022).

Schizophrenia is a common public health problem affecting 0.5–1% of adults around the world (Santos Febles et al., 2022). The onset of the disease usually happens in late adolescents and young adults when a person is still at an age where education, career development, and social connections play a very important role in one's life. People with schizophrenia also have a shorter life expectancy compared to the general population. Factors contributing to this disparity include comorbid physical illnesses, unhealthy lifestyle behaviours, limited access to healthcare, and a higher risk of suicide. Consequently, schizophrenia imposes a substantial burden on patients, caregivers, healthcare systems, and society (Raju, 2022).

Despite the availability of pharmacological and psychosocial therapies for the treatment of the condition, the existing approaches do not suffice in addressing all aspects of the disease especially cognitive impairment and negative symptoms. The progress that has been made in the areas of neuroscience, neuroimaging, and computer science has opened up new doors for the therapy and detection of the disease.

New technologies such as artificial intelligence and machine learning have enabled researchers to analyze large amounts of data collected through neuroimaging and genetic research and identify new biomarkers (Santos Febles et al., 2022). Combining insights from neuroimaging with the advances in computer technology could enhance diagnosis and facilitate the development of pharmacogenomics.

This literature review examines schizophrenia, emphasizing the latest neuroimaging and artificial intelligence researches.

II. ETIOLOGY AND RISK FACTORS

It should be noted that schizophrenia is considered a multifactorial condition caused by the interactions between genetics, biology, development, and environment. There is no single cause identified in the development of schizophrenia; there are several risk factors involved.

2.1. Genetic Contributions

Genetic susceptibility is an important factor in the development of schizophrenia. Several family, twin, and adoption studies have provided evidence of significant heritability, with an estimated range of heritability being 60% to 80%.

Genome-wide association studies (GWAS) have shown the involvement of many genetic markers that affect the development of schizophrenia. Several identified genes play a role in the development of synapses, neural transmissions, immune system function, and neurogenesis. Rare mutations like copy number variation (CNV) in which a deletion in chromosome 22q11.2 is one have been associated with schizophrenia.

The above information is supportive of the polygenetic hypothesis where schizophrenia is believed to be caused by genetic mutations in more than one gene.

2.2. Epigenetic Mechanisms

Epigenetics refers to processes that regulate gene expression without altering the genetic code of an organism. Main epigenetic processes include DNA methylation, histone modifications, and regulation of genes by non-coding RNA molecules(Jing et al., 2015).

Factors from the environment such as stress, infections, exposure to toxins, and childhood trauma could lead to epigenetic alterations which may affect brain development and function. Epigenetic modifications could affect the genes involved in synapses and neuronal plasticity thus causing schizophrenia.

2.3. Environmental and Developmental Factors

Environmental and developmental influences also contribute significantly to schizophrenia risk. Prenatal factors—including maternal infections, poor nutrition during pregnancy, and obstetric complications—have been linked to an increased risk of vulnerability to certain disorders. Other risk factors include perinatal hypoxia, childhood trauma, chronic stress, social isolation, and drug abuse, particularly the use of marijuana, during the teenage years. The above risk factors combine with genetics in affecting brain development and triggering disease(Moza & Chrysostomou, 2025).

III. NEUROBIOLOGY OF SCHIZOPHRENIA

The neurobiology of schizophrenia includes several changes in brain anatomy, neural circuits, and neurotransmitter systems. Several studies using neuroimaging and neurobiological techniques have shown that schizophrenia is characterized by several changes in brain organization and connectivity.

3.1. Neurotransmitter Dysregulation

Dopamine theory continues to be one of the most prominent theories of schizophrenia. Increased activity of the mesolimbic pathway due to increased dopamine has been linked to the appearance of psychotic symptoms like hallucinations and delusions.

Nevertheless, dopamine imbalance cannot account for all symptoms. Deficits in glutamatergic function, particularly impaired function of NMDA receptors, have been found to be related to cognitive impairment and negative symptoms. Moreover, GABA imbalances in synaptic transmission might interfere with inhibitory control of neural circuits(Göker, 2023; Moza & Chrysostomou, 2025; Raju, 2022).

Therefore, schizophrenia can be a consequence of interactions between several neurochemical processes.

3.2. Structural and Functional Brain Alterations

Research on brain imaging has uncovered structural alterations in a number of brain regions including the prefrontal cortex, hippocampus, thalamus, and temporal lobes.

The alterations include the following:

- Decreased gray matter volume
- Cortical thinning
- Ventricular enlargement

Using fMRI imaging, disruptions in major brain networks like the default mode network, salience network, and executive control network have been observed. The disturbances in neural connections may be responsible for cognitive disorders and poor information processing.

IV. CLINICAL FEATURES AND DIAGNOSIS

Schizophrenia is characterized by varying presentations depending on the patient. The signs of schizophrenia can be broadly categorized into three groups: positive, negative, and cognitive symptoms(De Filippis et al., 2019).

Hallucinations, delusions, and disorganized thinking are examples of positive symptoms. Examples of negative symptoms include lack of emotional response, low motivation, and social isolation. Attention deficits, working memory problems, and poor executive function are some cognitive symptoms(Chen et al., 2020).

Diagnosis is done through clinical assessment using criteria such as DSM-5 and ICD-11. Symptoms should have lasted for at least six months.

V. TREATMENT APPROACHES

Medication and psychosocial therapy are typically used in conjunction for effective treatment of schizophrenia.

5.1. Pharmacotherapy

Antipsychotics are still considered to be the first-line treatment option for schizophrenia because of their effects on dopamine D2 receptors that help reduce positive symptoms(Moza & Chrysostomou, 2025).

The major problems associated with antipsychotics include:

- Ineffectiveness with negative symptoms
- Lack of influence on cognitive problems
- Metabolic and neurologic side effects

Alternative approaches in treatment involve targeting other receptors including glutamate receptors and muscarinic acetylcholine receptors.

5.2. Psychosocial and Rehabilitation Interventions

Psycho-social interventions are critical to sustained recovery.

Examples of some key interventions are:

- Cognitive Behavior Therapy (CBT)
- Psycho-Education of Family
- Social Skills Training
- Supported Employment Programs
- Communitsy Rehabilitation Services

Digital Mental Health Technologies, including AI-driven ones, are being recognized as helpful interventions as well.

VI. EMERGING RESEARCH AND FUTURE DIRECTIONS

6.1. Multimodal Biomarkers

The merging of genomic information, neuroimaging findings, and electrophysiology measurements has made possible the development of multimodal biomarkers of schizophrenia. Machine learning algorithms are able to analyze complex data sets to find patterns associated with risk factors and disease progression.

6.2. High-Order Network Analyses

Graph theory and sophisticated connectivity analyses enable researchers to depict the brain as a complex network of interconnected regions. These methodologies assist in pinpointing unusual connectivity patterns linked to schizophrenia.

6.3. Cell-Based Models

Patient-derived induced pluripotent stem cells (iPSCs) and brain organoid models provide new approaches to study the cellular and molecular mechanisms of schizophrenia. These models allow the study of neurodevelopmental abnormalities under controlled laboratory conditions.

6.4. Precision Medicine

Precision medicine strives to tailor treatment strategies based on an individual's genetic, neurobiological, and environmental profile. Integrating neuroimaging, genomics, and artificial intelligence can provide personalized interventions and improve treatment outcomes.

VII. CONCLUSION

There have been tremendous strides made regarding the complex aspects of the genetic, neurobiological, and clinical concerns of schizophrenia. Improvements in neuroimaging technology and artificial intelligence have greatly improved the ability to investigate abnormality in the human brain and identify possible biomarkers.

All the above notwithstanding, there are still many strides that need to be made towards the successful application of the research in the diagnosis and treatment of Schizophrenia. More research needs to be conducted in the fields of neuroscience, genetics, psychiatry, and computer science in order to make future strides in the diagnosis and individualized treatment of schizophrenia.

REFERENCES

[1] Chen, Z. H., Yan, T., Wang, E. L., Jiang, H., Tang, Y. Q., Yu, X., Zhang, J., Liu, C., & Rostro-Gonzalez, H. (2020). Detecting Abnormal Brain Regions in Schizophrenia Using Structural MRI via Machine Learning. *Computational Intelligence and Neuroscience*, *2020*. https://doi.org/10.1155/2020/6405930

[2] De Filippis, R., Carbone, E. A., Gaetano, R., Bruni, A., Pugliese, V., Segura-Garcia, C., & De Fazio, P. (2019). Machine learning techniques in a structural and functional MRI diagnostic approach in schizophrenia: A systematic review. *Neuropsychiatric Disease and Treatment*, *15*, 1605–1627. https://doi.org/10.2147/NDT.S202418

[3] Göker, H. (2023). 1D-convolutional neural network approach and feature extraction methods for automatic detection of schizophrenia. *Signal, Image and Video Processing*, *17*(5), 2627–2636. https://doi.org/10.1007/s11760-022-02479-7

[4] Jing, Y., Shen, X., Mei, Q., & Han, W. (2015). Spotlight on decitabine for myelodysplastic syndromes in Chinese patients. *OncoTargets and Therapy*, *8*, 2783–2790. https://doi.org/10.2147/OTT.S81093

[5] Moza, S., & Chrysostomou, S. (2025). Perspective Chapter: The Neuropsychological Dimension of Psychosis – Implications for Assessment and Treatment. *Psychosis - From Cell to Society*. https://doi.org/10.5772/intechopen.1009026

[6] Raju, N. N. (2022). Psychiatry training in India. *Indian Journal of Psychiatry*, *64*(5), 433–439. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_649_22

[7] Agarwal, M., & Singhal, A. (2023). Fusion of pattern-based and statistical features for Schizophrenia detection from EEG signals. *Medical Engineering and Physics*, *112*(February), 1–7. https://doi.org/10.1016/j.medengphy.2023.103949

[8] Buettner, R., Beil, D., Scholtz, S., & Djemai, A. (2020). Development of a machine learning based algorithm to accurately detect schizophrenia based on one-minute EEG recordings. *Proceedings of the Annual Hawaii International Conference on System Sciences*, *2020-Janua*, 3216–3225. https://doi.org/10.24251/hicss.2020.393

[9] Cabral, C., Kambeitz-Ilankovic, L., Kambeitz, J., Calhoun, V. D., Dwyer, D. B., Von Saldern, S., Urquijo, M. F., Falkai, P., & Koutsouleris, N. (2016). Classifying Schizophrenia Using Multimodal Multivariate Pattern Recognition Analysis: Evaluating the Impact of Individual Clinical Profiles on the Neurodiagnostic Performance. *Schizophrenia Bulletin*, *42*(1), S110–S117. https://doi.org/10.1093/schbul/sbw053

[10] Chen, Z. H., Yan, T., Wang, E. L., Jiang, H., Tang, Y. Q., Yu, X., Zhang, J., Liu, C., & Rostro-Gonzalez, H. (2020). Detecting Abnormal Brain Regions in Schizophrenia Using Structural MRI via Machine Learning. *Computational Intelligence and Neuroscience*, *2020*. https://doi.org/10.1155/2020/6405930

[11] Jo, Y. T., Joo, S. W., Shon, S. H., Kim, H., Kim, Y., & Lee, J. (2020). Diagnosing schizophrenia with network analysis and a machine learning method. *International Journal of Methods in Psychiatric Research*, *29*(1), 1–11. https://doi.org/10.1002/mpr.1818

[12] Noor, M. B. T., Zenia, N. Z., Kaiser, M. S., Mamun, S. Al, & Mahmud, M. (2020). Application of deep learning in detecting neurological disorders from magnetic resonance images: a survey on the detection of Alzheimer's disease, Parkinson's disease and schizophrenia. *Brain Informatics*, *7*(1). https://doi.org/10.1186/s40708-020-00112-2

[13] Oh, J., Oh, B. L., Lee, K. U., Chae, J. H., & Yun, K. (2020). Identifying Schizophrenia Using Structural MRI With a Deep Learning Algorithm. *Frontiers in Psychiatry*, *11*. https://doi.org/10.3389/fpsyt.2020.00016

[14] Organisciak, D., Shum, H. P. H., Nwoye, E., & Woo, W. L. (2022). RobIn: A robust interpretable deep network for schizophrenia diagnosis. *Expert Systems with Applications*, *201*, 1–39. https://doi.org/10.1016/j.eswa.2022.117158

ISSN (Online) 2394-2320

International Journal of Engineering Research in Computer Science and Engineering (IJERCSE)

Volume 13, Issue 9, September 2026

[15] Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. *The Lancet*, *388*(10039), 86–97. https://doi.org/10.1016/S0140-6736(15)01121-6

[16] Raju, N. N. (2022). Psychiatry training in India. *Indian Journal of Psychiatry*, *64*(5), 433–439. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_649_22

[17] Rampisela, T. V., & Rustam, Z. (2018). Classification of Schizophrenia Data Using Support Vector Machine (SVM). *Journal of Physics: Conference Series*, *1108*(1). https://doi.org/10.1088/1742-6596/1108/1/012044

[18] Ruiz de Miras, J., Ibáñez-Molina, A. J., Soriano, M. F., & Iglesias-Parro, S. (2023). Schizophrenia classification using machine learning on resting state EEG signal. *Biomedical Signal Processing and Control*, *79*(April 2022). https://doi.org/10.1016/j.bspc.2022.104233

[19] Saher, A., Gilanie, G., Cheema, S., Latif, A., Batool, S. N., & Ullah, H. (2024). A Deep Learning-Based Automated Approach of Schizophrenia Detection from Facial Micro-Expressions. *Intelligent Automation and Soft Computing*, *39*(6), 1053–1071. https://doi.org/10.32604/iasc.2024.057047

[20] Samanta, M. K., Wesley, N. E. S., Manikandan, S. R., & Suresh, B. (2004). An overview of schizophrenia. *Indian Journal of Pharmaceutical Sciences*, *66*(2), 148–157.

[21] Santos Febles, E., Ontivero Ortega, M., Valdés Sosa, M., & Sahli, H. (2022). Machine Learning Techniques for the Diagnosis of Schizophrenia Based on Event-Related Potentials. *Frontiers in Neuroinformatics*, *16*(July), 1–11. https://doi.org/10.3389/fninf.2022.893788

[22] Suri, G. S., Kaur, G., & Moein, S. (2021). Machine learning in detecting schizophrenia: An overview. *Intelligent Automation and Soft Computing*, *27*(3), 723–735. https://doi.org/10.32604/IASC.2021.015049

[23] Bae, Y. J., Shim, M., & Lee, W. H. (2021). Schizophrenia detection using machine learning approach from social media content. *Sensors*, *21*(17). https://doi.org/10.3390/s21175924

[24] Ruiz de Miras, J., Ibáñez-Molina, A. J., Soriano, M. F., & Iglesias-Parro, S. (2023). Schizophrenia classification using machine learning on resting state EEG signal. *Biomedical Signal Processing and Control*, *79*(April 2022). https://doi.org/10.1016/j.bspc.2022.104233

[25] Sahu, P. K. (2023). Artificial intelligence system for verification of schizophrenia via theta-EEG rhythm. *Biomedical Signal Processing and Control*, *81*(March), 23–25. https://doi.org/10.1016/j.bspc.2022.104485

[26] Wang, D., Russel, W. A., Sun, Y., Belanger, K. D., & Ay, A. (2023). Machine learning and network analysis of the gut microbiome from patients with schizophrenia and non-psychiatric subject controls reveal behavioral risk factors and bacterial interactions. *Schizophrenia Research*, *251*(January), 49–58. https://doi.org/10.1016/j.schres.2022.12.015

[27] Zbello, B. T. (2020). *Schizophrenia Disease Classification with Deep learning and Convolutional Neural Network Architectures using TensorFlow MASTER THESIS Title : Schizophrenia Disease Classification with Deep learning and Convolutional Neural Network Architectures using Tens* (Number May).

[28] De Filippis, R., Carbone, E. A., Gaetano, R., Bruni, A., Pugliese, V., Segura-Garcia, C., & De Fazio, P. (2019). Machine learning techniques in a structural and functional MRI diagnostic approach in schizophrenia: A systematic review. *Neuropsychiatric Disease and Treatment*, *15*, 1605–1627. https://doi.org/10.2147/NDT.S202418